Altnia Group

Altnia is a Barcelona-based biotechnology company dedicated to the development of innovative therapies for age-related diseases through cellular rejuvenation. The company utilizes an epigenetic reprogramming platform to reset the biological age of cells in vivo, aiming to restore youthful function to damaged or aged tissues. Altnia's primary focus areas include ophthalmology, specifically age-related macular degeneration, and neurodegenerative disorders. By targeting the fundamental drivers of aging rather than individual symptoms, Altnia seeks to develop a new class of regenerative medicines that can significantly extend healthy lifespan and improve patient outcomes in chronic conditions. The company is led by experienced biotech entrepreneurs and is part of a growing global ecosystem focused on longevity and regenerative medicine.